Latest Breaking News On - Nicolas girard - Page 1 : comparemela.com

MVNO platform looks to add connectivity, not complexity

MVNO platform looks to add connectivity, not complexity
lightreading.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lightreading.com Daily Mail and Mail on Sunday newspapers.

United statesNicolas girardLatin america

J&J: positive CHMP opinion for lung cancer

J&J: positive CHMP opinion for lung cancer
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Nicolas girardInstitut curieHead of the medical oncology departmentProfessor nicolas girardMedical oncology departmentThoracic oncologyRespiratory medicineParis saclay

Johnson & Johnson receives positive CHMP opinion for

This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of.

France generalRegion flamandeUnited statesNicolas girardHenar heviaInstitut curieParis saclay universityEuropean medicines agencyEuropean society for medical oncology congressExchange commissionEuropean unionAmerican lung associationJanssen biotech incEuropean medicines agency seeking approvalEuropean commissionCommittee for medicinal products human use

Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations

Media contact: Investor contact: .

Region flamandeFrance generalInstitut curieHenar heviaNicolas girardZayn qureshiEuropean medicines agencyJanssen cilag internationalParis saclay universityCommittee for medicinal products human useCilag internationalMedicinal productsHuman useProfessor nicolas girardMedical oncologyThoracic oncology

Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC

Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.

Saint quentinChampagne ardenneFrance generalHenar heviaKiran patelNicolas girardInstitut curieCurie montsouris thorax instituteClinical developmentJohnson research developmentVersailles saint quentin universityEuropean medicines agencyMedicinal productsHuman useArea leadJohnson innovative medicine